MARKET WIREBenzinga • 2d ago
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For FridayAnalysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).
Why CLOV Stock dropped -4.38% Today — RQD Quant Desk Flash
$4.58 -4.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Clover Health Investments Corp. (Class A) (CLOV) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $2.43B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLOV)Realized 20D OHLCV Swing Band: ±10.6%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CLOV Stock dropped -4.38% Today — RQD Quant Desk Flash
Clover Health Investments Corp. (Class A) (CLOV) dropped -4.38% to $4.58, trading at 75% of its 52-week range ($1.58 – $5.59). Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 75% of its 52-week range ($1.58 – $5.59) with RSI-14 at 45.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.6% around $4.58 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CLOV Headlines & Catalysts
MARKET WIREBenzinga • 3d ago
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For ThursdayAnalysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
MARKET WIREYahoo • 3d ago
3 Big reasons to love Clover Health (CLOV)What a time it’s been for Clover Health. In the past six months alone, the company’s stock price has increased by a massive 74.4%, reaching $4.61 per share. This was partly due to its solid quarterly results, and the run
MARKET WIREYahoo • 4d ago
Clover Health climbs after Needham initiates coverage with Buy, $6 targetInvesting.com -- Clover Health Investments Corp (NASDAQ:CLOV) shares advanced 4% in Wednesday trading after Needham initiated coverage on the healthcare technology company with a Buy rating and a $6.00 price target. The
MARKET WIREBenzinga • 4d ago
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayAnalysts initiated coverage: Hold ALHC; Overweight/$6 SPRO; Buy/$3 LABT; Buy/$6 CLOV.
MARKET WIREBenzinga • 4d ago
Needham Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6Needham analyst Matthew Shea initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Buy rating and announces Price Target of $6.
MARKET WIREYahoo • 6d ago
Clover Health to Participate in Upcoming UBS Global Healthcare ConferenceWILMINGTON, Del., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Officer, Clay Thornton, w
MARKET WIREYahoo • 12d ago
Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three StatesClover Health plans are named Best Medicare Advantage Plans in New Jersey, Georgia, and South Carolina, scoring highest in all three states for Best for Care Continuity.WILMINGTON, Del., Oct. 19, 2026 (GLOBE NEWSWIRE) --
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLOV)
- ✓Walkthrough of CLOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CLOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.55%▲ ASCENDING TRIANGLE
2026-10-30O $4.53H $4.58L $4.34C $4.58VOL 4.65M
RES: $5.22SUP: $4.17SMA50: $4.51SMA200: $3.54
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CLOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +40.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CLOV today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CLOV. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLOV)
Health Care Rank #939 of 1016
⚔️ FTRE vs CLOV Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CLOV vs. FTRE, ACHC, CELC, PSNL)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Clover Health Investments Corp. (Class A) (CLOV) ranks #939 by composite RQD confidence (30/100, grade E) and #224 by equity capitalization ($2.43B). Within this direct 5-issuer industry benchmark cohort, CLOV leads on earnings valuation at N/A trailing P/E, while ACHC leads on capital efficiency and profitability with -24.8% ROIC and — gross margin. ACHC currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with CLOV at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CLOV
ACTIVE
Clover Health Investments Corp. (Class A) | E | 30/100 | — | — | -29.3% | -4.38% | $2.43B | Benchmark Subject |
| FTRE Fortrea Holdings Inc. | D- | 35/100 | — | — | -35.0% | -10.61% | $2.20B | /ftre-vs-clov → |
| ACHC Acadia Healthcare Company Inc. | D- | 37/100 | — | — | -24.8% | -0.17% | $2.74B | /achc-vs-clov → |
| CELC Celcuity Inc. | D- | 36/100 | — | — | -35.0% | -0.23% | $3.39B | /celc-vs-clov → |
| PSNL Personalis Inc. | D- | 36/100 | — | 22.7% | -35.0% | -0.47% | $1.70B | /psnl-vs-clov → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001801170In its most recent audited fiscal period (FY2025, filed 2025-12-31), Clover Health Investments Corp. (Class A) (CLOV) reported GAAP revenue of $1.92B (+40.3% vs. FY2024 revenue of $1.37B , and +52.7% cumulative change since FY2023) , GAAP net income of -$85.5M, operating cash flow of -$66.9M, and free cash flow of -$69.0M (-307.2% YoY). On the balance sheet, CLOV closed FY2025 with $541.0M in total assets against $0 in total debt (Altman Z-Score: 3.62, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.92B | -$85.5M | -$66.9M | -$69.0M | $541.0M | — |
| FY2024 (FY) | 2024-12-31 | $1.37B | -$43.0M | $34.8M | $33.3M | $580.7M | — |
| FY2023 (FY) | 2023-12-31 | $1.26B | -$213.4M | -$144.7M | -$144.7M | — | — |
3. CLOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CLOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Clover Health Investments Corp. (Class A) (NASDAQ: CLOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.58 (-4.38% 1D, market cap $2.43B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLOV ranks #939 in composite RQD confidence.
How does CLOV compare to FTRE and ACHC in the Health Care sector?
Within the Health Care sector (Medical Specialities), CLOV carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.3%. By comparison, FTRE (Fortrea Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -24.8%, cap $2.74B). Among the 5-stock peer group, CLOV leads on earnings multiple (N/A) while ACHC leads on capital efficiency (-24.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CLOV?
Per CLOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801170), Clover Health Investments Corp. (Class A) generated $1.92B in revenue (+40.3% YoY), -$85.5M in net income, and -$69.0M in free cash flow against $541.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CLOV trading relative to its 50-day, 200-day, and 52-week technical levels?
CLOV last traded at $4.58 (-4.38% on volume of 4,070,913 shares), positioning the stock +1.55% above its 50-day simple moving average ($4.51) and +29.38% above its 200-day simple moving average ($3.54). Across its 52-week range of $1.58 to $5.59, CLOV sits at the 74.8% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.6% ($4.09 to $5.07).
CLOV Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CLOV stock moving today?
Why CLOV Stock dropped -4.38% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.